Results 31 to 40 of about 19,218 (261)

Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy

Clinical, Cosmetic and Investigational Dermatology, 2017
Zoe Apalla,1 Chrysoula Papageorgiou,1 Aimilios Lallas,1 Elena Sotiriou,1 Elizabeth Lazaridou,1 Efstratios Vakirlis,1 Athanassios Kyrgidis,2 Demetrios Ioannides1 1First Department of Dermatology, Aristotle University, 2Department of Oral and Maxillofacial
Apalla Z, Papageorgiou C, Lallas A, Sotiriou E, Lazaridou E, Vakirlis E, Kyrgidis A, Ioannides D   +7 more
doaj   +1 more source

Vismodegib for treatment of periocular basal cell carcinoma – 6-year experience from a tertiary cancer center, [PDF]

Anais Brasileiros de Dermatologia, 2022
Background: The treatment of advanced periocular basal cell carcinomas becomes a challenge as surgery may involve highly mutilating procedures. Vismodegib is the first selective hedgehog inhibitor approved for the treatment of locally advanced tumors or ...
Catarina Xavier, Edgar Lopes, Catarina Bexiga, Cecília Moura, Emanuel Gouveia, Ana Filipa Duarte   +5 more
doaj   +1 more source

Vismodegib y sonidegib en el carcinoma de células basales localmente avanzado y metastásico: actualización acerca de los inhibidores de la vía de Hedgehog

Actas Dermo-Sifiliográficas, 2022
Resumen: El carcinoma de células basales (CBC) es una de las neoplasias malignas más frecuentes, por lo que se ha convertido en una importante carga asistencial. Su incidencia se incrementa anualmente, especialmente en la población con mayor edad.
J. Kurnia Wijaya, K. Djawad, S. Wahab, A. Nurdin, A. Irawan Anwar   +4 more
doaj   +1 more source

Cutaneous Squamous Cell Carcinoma While on Vismodegib Therapy for Locally Advanced Basal Cell Carcinoma

Actas Dermo-Sifiliográficas
B. Sánchez Lafuente, P.J. Vera García, P. Cerezuela Fuentes   +2 more
doaj   +3 more sources

Baseline disease characteristics in patients with locally advanced basal cell carcinoma in Cohort 1.

, 2022
Baseline disease characteristics in patients with locally advanced basal cell carcinoma in Cohort 1.
Simon Yoo (11949194), Aleksandar Sekulic (3192720), Laura Chu (1891477), Edward McKenna (4030052), Yong Mun (9200749), Julie Guillen (11949200), Ragini Kudchadkar (11949197), Gary Rogers (505210), Keith Dawson (11949209), Scott Guenthner (11949203), Mario Lacouture (11949212), Anne Lynn S. Chang (3339900), Bernard Raskin (11949206)   +12 more
core   +1 more source

Determination of locally advanced basal cell carcinoma in patients in Cohort 1.

, 2022
Determination of locally advanced basal cell carcinoma in patients in Cohort 1.
Simon Yoo (11949194), Aleksandar Sekulic (3192720), Laura Chu (1891477), Edward McKenna (4030052), Yong Mun (9200749), Julie Guillen (11949200), Ragini Kudchadkar (11949197), Gary Rogers (505210), Keith Dawson (11949209), Scott Guenthner (11949203), Mario Lacouture (11949212), Anne Lynn S. Chang (3339900), Bernard Raskin (11949206)   +12 more
core   +1 more source

Clinical Clearance Following Improvement of Histologic Subtype of Basal Cell Carcinoma with Sonidegib

Acta Dermato-Venereologica, 2022
is missing (Short communication)
Liang Joo Leow, Vicki Howard
doaj   +1 more source

Baseline demographics in patients with locally advanced basal cell carcinoma in Cohort 1.

, 2022
Baseline demographics in patients with locally advanced basal cell carcinoma in Cohort 1.
Simon Yoo (11949194), Aleksandar Sekulic (3192720), Laura Chu (1891477), Edward McKenna (4030052), Yong Mun (9200749), Julie Guillen (11949200), Ragini Kudchadkar (11949197), Gary Rogers (505210), Keith Dawson (11949209), Scott Guenthner (11949203), Mario Lacouture (11949212), Anne Lynn S. Chang (3339900), Bernard Raskin (11949206)   +12 more
core   +1 more source

New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma

, 2022
Non-melanoma skin cancers, also known as keratinocyte tumors, have an increasing incidence worldwide, with basal cell carcinoma and squamous cell carcinoma being the most represented ones.
Fabbrocini G., Villani A., Scalvenzi M., Potestio L.   +3 more
core   +1 more source

Vismodegib for giant, locally advanced, basal cell carcinoma and its complex position in clinical practice. [PDF]

JAAD Case Rep, 2019
Koekelkoren FHJ, Roodbergen SL, Baerveldt EM, Maat APWM, Monserez DA, Grünhagen DJ, Mureau MAM, de Haas ERM, Nijsten TEC, Wakkee M.   +9 more
europepmc   +2 more sources